ProtonDx designs and manufacturers, rapid, accurate, multi-pathogen molecular diagnostics for use at the point-of-care.
DragonflyTM Respiratory Panel
In mid-2022 ProtonDx launched the CE-IVD DragonflyTM molecular diagnostic platform with a Respiratory Panel, detecting the presence of RSV, SARS CoV 2, Influenza A, Influenza B, and Human rhinovirus, from a single respiratory swab sample, in under 30 minutes.
During the CE‑IVD marking process, performance studies indicated Dragonfly’s specificity at 100%, sensitivity at 97.53% and LOD at 500 copies/ml. Additionally, the DragonflyTM Respiratory Panel has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) Regulations 2021 (CTDA), with data indicating 100% Sensitivity and 100% Specificity.
The speed and portability of the Dragonfly platform potentially offers many benefits to both clinicians and patients by bringing lab accurate results to the point-of-care, enabling rapid clinical decision making and earlier treatment.
Contact ProtonDx
+44 (0) 208 1507620
POCT-for-Scot Ltd has undertaken a comprehensive evaluation of the Dragonfly device and sample preparation kit to determine the ease of adoption for the device in a variety of Point of Care settings. To view the full report or to download, please click below:
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.